By April 2023, RC108 had been approved for Phase 1b/2 clinical research in China targeting locally advanced or metastatic NSCLC with EGFR mutations that had failed c-MET expression treatment with EGFR-TKIs (ClinicalTrials.gov identifiers: NCT05821933). Here, EGFR is linked to non-small cell lung carcinoma.